Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.46 |
| ▸ | CDK2 | P24941 | 6/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PDE8A | O60658 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2848856 | 0.86 | CCNA2 (0.41) | ADORA2ACDK1CDK5CDK5R1CCNA2 | |
| SCHEMBL29426182 | 0.80 | CDK2 (0.56) | ADORA2ACDK1CDK5CDK5R1CCNA2 | |
| SCHEMBL539356 | 0.80 | CDK2 (0.56) | ADORA2ACDK1CDK5CDK5R1CCNA2 | |
| SCHEMBL27897027 | 0.77 | CDK2 (0.44) | CDK1CDK5CDK5R1CCNA2CDK2 | |
| SCHEMBL9080110 | 0.77 | MEN1 (0.47) | ADORA2ACDK1MEN1HPGDKMT2A | |
| SCHEMBL10589023 | 0.75 | MEN1 (0.51) | ADORA2ACDK1MEN1HPGDKMT2A | |
| SCHEMBL30331956 | 0.75 | ADORA2A (0.50) | ADORA2ACDK1CDK5CDK5R1CCNA2 | |
| SCHEMBL946328 | 0.75 | ADORA2A (0.50) | ADORA2ACDK1CDK5CDK5R1CCNA2 | |
| SCHEMBL25211412 | 0.73 | P2RX7 (0.41) | CDK1CDK5CDK5R1CCNA2CDK2 | |
| SCHEMBL6768493 | 0.73 | CDK1 (0.37) | ADORA2ACDK1CDK5CDK5R1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189730-B2 | A2A adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1456209-B1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1456209-A1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20030149060-A1 | A2A adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003051882-A1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-06-26 | — | — | WO | disclosed |
| US-5583137-A | Heterocyclic compounds for enhancing antitumor activity | PFIZER INC. (US) | 1996-12-10 | — | — | US | disclosed |
| EP-0626964-A1 | HETEROCYCLIC COMPOUNDS FOR ENHANCING ANTITUMOR ACTIVITY | PFIZER INC. (US) | 1994-12-07 | — | — | EP | disclosed |
| WO-1993017021-A1 | HETEROCYCLIC COMPOUNDS FOR ENHANCING ANTITUMOR ACTIVITY | PFIZER, INC. (US) | 1993-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149060-A1 | A2A adenosine receptor antagonists | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885CDK1 1472/4885MEN1 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.